<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78884">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01850446</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-ER-003</org_study_id>
    <nct_id>NCT01850446</nct_id>
  </id_info>
  <brief_title>Comparative Clinical Trial of Efficiency and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza</brief_title>
  <official_title>Comparative Parallel-group Randomized Clinical Trial of Efficiency and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to assess efficiency of Ergoferon for treatment of influenza;

        -  to assess safety of Ergoferon for treatment of influenza;

        -  to compare efficiency of Ergoferon and Oseltamivir for treatment of influenza.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall duration of a patient participation in the trial is 6 days
      (screening/randomization/therapy onset - day 1; study therapy period - day 1-5;  follow-up
      period - day 6).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patient demonstrating recovery/ improvement  in health</measure>
    <time_frame>On day 2, 3, 4 and 5 of the treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on the results of objective examination conducted by a physician;
Recovery criteria: body temperature ≤37.0° C +  lack of symptoms; Improvement criteria: body temperature ≤37.2 ° C + total intensity of all symptoms (except for fever index) ≤2 scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamics of fever</measure>
    <time_frame>On day 2, 3, 4 and 5 of the treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in body temperature on day 2, 3, 4 and 5 of the treatment in comparison with the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average duration of fever</measure>
    <time_frame>6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Criteria of no fever - body temperature lower than 37.0° C for 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normal body temperature (no more than 37.0ºС)</measure>
    <time_frame>On day 2, 3, 4, 5 of the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of clinical manifestations of influenza (fever, general symptoms and nasal/ throat/ chest symptoms) in scores</measure>
    <time_frame>On day 1, 2, 3, 4 and 5 of the treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on the result of objective examination conducted by a physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of major clinical symptoms of influenza(fever, general symptoms and nasal/ throat/ chest symptoms) in days</measure>
    <time_frame>6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on the result of objective examination conducted by a physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of influenza course</measure>
    <time_frame>On day 1, 2, 3, 4 and 5 of the treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on the data on area under curve for total index of influenza severity; based on the results of objective examination conducted by a physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of antipyretics administration on day 1, 2, 3, 4 and 5 of the treatment</measure>
    <time_frame>Day 1, 2, 3, 4 and 5 of the treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antipyretics, which are allowed for use during clinical trial, are:
Paracetamol;
Metamizole sodium (if hyperthermia was not stopped by usage of paracetamol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients, who used antipyretics</measure>
    <time_frame>On day 1, 2, 3, 4 and 5 of the treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with the development of disease complications requiring antibiotics administration, and of patients with exacerbation of the disease course (the development of severe influenza)</measure>
    <time_frame>6 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with negative results of virology assay</measure>
    <time_frame>On day 3, 4, 5 and 6 of observation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on the data on PCR of nasal sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of parameters of immune status</measure>
    <time_frame>On day 1, 3 and 6 of observation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parameters of phagocytosis of peripheral blood macrophages (on day 1, 3 and 6 of observation);
Concentration of regulators of T- cell immune response - IL2, IFN -γ, IL-18 (on day 1,3 and 6 of observation) and regulators of В-cellular antigen-specific immune response - IL-4, IL-16 (on day1, 3 and 6 of observation);
Level of leukocytes spontaneous and induced in vitro production of IFN-α and IFN-γ (on day 1, 3 and 6 of observation);
Absolute count of leukocytes, absolute and relative count of neutrophils, lymphocytes, monocyte, eosinophils, basophils on day 1, 3 and 6 of observation;
The peculiarities of leukocyte phenotype in the dinamyc of the disease course - absolute and relative count of CD3, CD4, CD8, CD4/CD8; leukocyte CD16, CD119 (on day 1, 3 and 6 of observation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Ergoferon (1 tablet 3 times a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir (Tamiflu) - 1 capsule (75mg) two times a day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergoferon</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Ergoferon (1 tablet 3 times a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Oseltamivir (Tamiflu) - 1 capsule (75mg) two times a day</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged from 18 to 70 years inclusively.

          2. Patients, who were admitted to hospital within 48 hours from the onset of influenza
             signs.

          3. Patients with body temperature ≥37,8°C when visiting a doctor + intensity of
             influenza symptoms ≥4 score (presence of at least 1 general symptom ≥2 scores and 1
             nasal/ throat/ chest symptom ≥ 2 scores or greater number of symptoms with the
             intensity ≥1 score).

          4. Diagnosed influenza confirmed by express diagnostics (OSOM Influenza A&amp;B Test).

          5. The possibility to start therapy within 48 hours after the onset of the first
             symptoms of influenza.

          6. Usage of contraceptive methods by both gender patients of reproductive age during the
             trial and within 30 days after ending the participation in the trial.

          7. Availability of signed patient information sheet (Informed Consent form) for
             participation in the clinical trial.

        Exclusion Criteria:

          1. Suspected pneumonia.

          2. Suspected initial manifestations of diseases that have symptoms similar to influenza
             symptoms (other acute respiratory and infectious diseases, influenza-like syndrome at
             the onset of systemic connective tissue disorders, oncohematology and other
             pathology).

          3. Patients requiring competitive antiviral drugs, which are prohibited during this
             trial.

          4. Medical history of primary and secondary immune deficiency: a) lymphoid system
             immunodeficiency (T-cell and/or B-cell immunity chain, immunodeficiency with
             predominant antibody deficiency); b) phagocyte deficiency; c) complement factors
             deficiency; d) combined immunodeficiency including AIDS induced by HIV infection;
             toxic, autoimmune, infectious, radial panleukopenia syndrome; general lymphocytopenia
             syndrome; syndrome of lymphocyte polyclonal activation; postsplenectomia syndrome;
             congenital asplenia; syndrome of immune complexes pathology associated with
             infectious, allergic and autoimmune diseases.

          5. Medical history of sarcoidosis.

          6. Oncological disease/suspected oncological disease.

          7. Exacerbation or decompensation of chronic diseases affecting the patient's  ability
             to participate in the clinical trial.

          8. Medical history of polyvalent allergy.

          9. Allergy/ intolerance to any of the components of medications used in influenza
             treatment.

         10. Impaired glucose tolerance, type 1 and 2 diabetes mellitus.

         11. Malabsorption syndrome, including congenital or acquired lactose deficiency or any
             other disaccharide deficiency.

         12. Exacerbation or decompensation of chronic diseases affecting patient's ability to
             participate in the trial.

         13. Pregnancy and breast feeding.

         14. Drug addiction, alcohol usage in the amount exceeding 2 units of alcohol per day,
             mental disorders.

         15. Intake of medicines listed in the section &quot;Prohibited concomitant treatment&quot; for 1
             month prior to the inclusion in the trial.

         16. Patients, who from the investigator's point of view, will fail to comply with the
             observation requirements of the trial or with the intake regimen of the investigated
             medicines.

         17. Participation in other clinical trials in the course of 1 month prior to the
             inclusion in the trial.

         18. Patient is related to the research personnel of the investigative site, who are
             directly involved in the trial or are the immediate family member of the researcher.
             The immediate family members includes husband/wife, parents, children or brothers (or
             sisters), regardless of whether they are natural or adopted.

         19. Patient works for OOO &quot;NPF &quot;Materia Medica Holding&quot; (i.e. is the company's employee,
             temporary contract worker or appointed official responsible for the carrying out the
             research) or the immediate relative.

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal State Budgetary Military Educational Institution of Higher Professional Education &quot;Military-Medicine Academy named after S. M. Kirov&quot; of Ministry of Defence of Russian Federation</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
